Desk› Healthcare› Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd

BSE 532296 GLENMARK INE935A01035

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals NIFTY 500

Filing rhythm · 60 trading days

31 filings · 15 material · busiest 2026-07-31

What it files

Press Release10 General4 Analyst / Investor Meet4 Concall Transcript2 Investor Presentation2 AGM / EGM1 Annual Report1 BRSR1

Filings

31 in the window

21 August 2026

Press Release

Press Release / Media Release

Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy ....

Company Update / Press Release / Media Release View filing →
20 August 2026

Press Release

Press Release / Media Release

Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray

Company Update / Press Release / Media Release View filing →
13 August 2026

AGM / EGM

Notice Of The 48Th Annual General Meeting For The Financial Year 2025-26

Please find attached Notice of 48th Annual General Meeting for the Financial Year 2025-26

AGM/EGM / AGM View filing →
13 August 2026

Annual Report

Reg. 34 (1) Annual Report.

Please find attached Notice convening the 48th Annual General Meeting and the Integrated Annual Report including BRSR for the Financial Year 2025-26.

Others / Reg. 34 (1) Annual Report View filing →
13 August 2026

BRSR

Business Responsibility and Sustainability Reporting (BRSR)

Please find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-26

Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
13 August 2026

General

Letter To Shareholders Whose Email Address Are Not Registered Providing The Web Link Of Annual Report

Letter to Shareholders whose email address are not registered providing the web link of Annual Report

Company Update / General View filing →
11 August 2026

General

Settlement Agreement - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015

Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Company Update / General View filing →
10 August 2026

ESOP Allotment

Allotment of ESOP / ESPS

Intimation of Allotment of shares under the Employee Stock Option Plan 2016

Company Update / Allotment of ESOP / ESPS View filing →
7 August 2026

Newspaper Publication

Newspaper Publication

Newspaper Advertisement regarding the 48th Annual General Meeting ("the AGM") to held through Video Conferencing ("VC")/ Other Audio-Visual Means ("OAVM")

Company Update / Newspaper Publication View filing →
7 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation of Schedule of Analyst / Institutional Investor Meetings

Company Update / Analyst / Investor Meet View filing →
5 August 2026

Concall Transcript

Earnings Call Transcript

Transcript of the Earnings Call

Company Update / Earnings Call Transcript View filing →
3 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Outcome

Audio recording of Q1 FY 2026-27 Earnings Call held on August 03, 2026

Company Update / Analyst / Investor Meet View filing →
31 July 2026

Board Outcome

Board Meeting Outcome for Board Meeting Outcome - Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2026

The Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

Board Meeting / Outcome of Board Meeting View filing →
31 July 2026

Record Date

Intimation Of Record Date For Dividend

Intimation of Record Date for Dividend

Corp. Action / Record Date View filing →
31 July 2026

General

Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - List Of Officials

Please find attached Company's officials authorised for the purpose of determining materiality of an event or information and making disclosures to the Stock Exchanges

Company Update / General View filing →
31 July 2026

Press Release

Press Release / Media Release

Please find attached Press Release and Management Discussion & Analysis for the first quarter ended June 30, 2026

Company Update / Press Release / Media Release View filing →
31 July 2026

Investor Presentation

Investor Presentation

Investor Presentation - Q1 FY 26-27

Company Update / Investor Presentation View filing →
28 July 2026

Press Release

Press Release / Media Release

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Company Update / Press Release / Media Release View filing →
21 July 2026

Press Release

Press Release / Media Release

Glenmark receives U.S. FDA approval to expand the use of RYALTRIS Nasal Spray for Children aged 6 to less than 12 years

Company Update / Press Release / Media Release View filing →
21 July 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation of Earnings Call

Company Update / Analyst / Investor Meet View filing →
15 July 2026

Board Meeting

Board Meeting Intimation for Considering And Approving Unaudited Financial Results Of Glenmark Pharmaceuticals Limited For The Quarter Ended June 30, 2026

Glenmark Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the Unaudited Financial ....

Board Meeting / Board Meeting View filing →
6 July 2026

Press Release

Press Release / Media Release

Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single - Dose Vial

Company Update / Press Release / Media Release View filing →
2 July 2026

Press Release

Press Release / Media Release

Glenmark advances Multi-Country Phase 3 Clinical Trial of Trastuzmab rezetecan in Platinum-Resistant Ovarian Cancer

Company Update / Press Release / Media Release View filing →
30 June 2026

General

Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

US FDA inspection at Company's manufacturing facility in Goa, India

Company Update / General View filing →
25 June 2026

Trading Window

Closure of Trading Window

Intimation of Closure of Trading Window

Insider Trading / SAST / Closure of Trading Window View filing →
25 June 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation of schedule of analyst / institutional investor meeting

Company Update / Analyst / Investor Meet View filing →
17 June 2026

Press Release

Press Release / Media Release

Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10mL (5 mg/mL) Single-Dose vial

Company Update / Press Release / Media Release View filing →
11 June 2026

Press Release

Press Release / Media Release

Glenmark launches Winlevi (clascoterone) 10 mg/g cream in Key European Markets for the Treatment of Acne Vulgaris

Company Update / Press Release / Media Release View filing →
9 June 2026

Investor Presentation

Investor Presentation

Please find attached Investor Presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2026 today.

Company Update / Investor Presentation View filing →
5 June 2026

Press Release

Press Release / Media Release

Glenmark Pharmaceuticals Inc., USA launches Lacosamide Injection USP, 200 mg/ 20mL (10 mg/mL), Single-Dose Vials

Company Update / Press Release / Media Release View filing →
5 June 2026

Concall Transcript

Earnings Call Transcript

Transcript of the Earnings call has been uploaded on Company's website

Company Update / Earnings Call Transcript View filing →